Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Zander Therapeutics, Inc | zander123118form10q.htm |
| EX-10.1 - EXHIBIT 10.1 - Zander Therapeutics, Inc | ex10_1.htm |
| EX-32.2 - EXHIBIT 32.2 - Zander Therapeutics, Inc | ex32_2.htm |
| EX-31.2 - EXHIBIT 31.2 - Zander Therapeutics, Inc | ex31_2.htm |
| EX-31.1 - EXHIBIT 31.1 - Zander Therapeutics, Inc | ex31_1.htm |
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly report of Zander Therapeutics, Inc. (the “Company”) on Form 10-Q for the quarter ended December 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: January 22, 2019 | By: | /s/ David R. Koos |
| David
R. Koos Chief Executive Officer |
A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002, or other document authentications, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Zander Therapeutics, Inc. and will be retained by Zander Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request